China: Food and Drugs Law

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

The Regulatory Data Protection Regime In China (Draft For Comments)

The National Medical Products Administration (NMPA) issued the Implementation Measures for Drug Regulatory Data Protection and the Drug Regulatory Data Protection Working Procedures on March 19, 2025.

China Healthcare

FP

Fangda Partners

澳门特区专利药品及植物药剂产品保护补充证明书制度解析

我国澳门特别行政区依托...

CP

CCPIT Patent & Trademark Law Office

中国创新药械全球崛起法律保障系列文章之一：创新药研发企业临床试验数据对外跨境传输的监管要点

得益于药品上市许可持有人制度确立、药品审评审批制度改革、专利链接制度...

AB

AnJie Broad Law Firm

China Advances Pharmaceutical Data Protection Regime With New Draft Measures

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Measures for the Protection of Drug Trial Data...

China Healthcare

AO

A&O Shearman

马库什化合物专利申请中，这4个缺陷一定要规避！

K

Kangxin

China Introduces A New Regulatory Data Protection And Exclusivity Mechanism

China Healthcare

AP

Arnold & Porter

Interpretation Of The Anti-Monopoly Guidelines For Pharmaceutical Sector: Key Risk Considerations

China Healthcare

AB

AnJie Broad Law Firm

Six Key Insights Into China Biotech's NewCo Model

China Healthcare

HK

Han Kun Law Offices

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

R

Rouse

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

转用发明创造性浅析

CP

CCPIT Patent & Trademark Law Office

从"AB酶"系列案件看商标法第十条一款七项的适用

CP

CCPIT Patent & Trademark Law Office

《关于药品领域的反垄断指南》解读：药企反垄断风险"划重点"

China Healthcare

AB

AnJie Broad Law Firm

Application Of Bioisosterism In The Judgment Of Inventiveness

AC

AFD China

中国自贸区数据出境负面清单管理模式与要点解读

China International

AB

AnJie Broad Law Firm

万能险新规解读

China Insurance

AB

AnJie Broad Law Firm

行业转型背景下汽车产业人员优化的法律分析及执行要点

AB

AnJie Broad Law Firm

This Is (Still) China (Video)

China Commercial

HS

Harris Sliwoski

中国公司控制权之争系列分析——完善少数股东权益保护

China Commercial

JT

Jincheng Tongda & Neal

東陽光薬、中国特許金賞を受賞　国際特許出願で世界展開を加速

広東東陽光薬業公司（以下、東陽光薬）が第25回中国...

K

Kangxin

China On The Move: Lessons From China's 2024 National Negotiation Of Drug Prices

China's share of the global drug development pipeline grew from 3% in 2013 to 28% in 2023, positioning China as the second-largest region for clinical trials after the United States.

China Healthcare

GT

Greenberg Traurig, LLP

CN Final Antimonopoly Guidelines For The Pharmaceutical Sector

Thanks for the notification from Aaron Wininger of Schwegman Lundberg & Woessner, P.A. , the China State Administration for Market Regulation SAMR announced the finalized...

TM

Toby Mak

China Unveils New Anti-Monopoly Guidelines For The Pharmaceutical Sector

China's State Council issued new Anti-Monopoly Guidelines for the Pharmaceutical Sector (the "Guidelines") effective January 24, 2025.

China Anti-trust

JD

Jones Day

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

医药企业申请商标的注意事项

CP

CCPIT Patent & Trademark Law Office

China Announces Major Policy Incentives For Life Sciences Companies

China Healthcare

RG

Ropes & Gray LLP

中美两国药品专利链接制度的比较

CP

CCPIT Patent & Trademark Law Office

26 Noteworthy Things About China's PTA And PTE System

NT

NTD Patent & Trademark Agency

Measures For Supervision And Administration Of The Quality Of Drug Supply And Use

China Healthcare

CC

CMS, China

Cannabis Law And Legislation In China

CC

CMS, China

Supreme People's Court Issued Interpretation On Punitive Damages For Food And Drug Disputes

China Healthcare

CC

CMS, China

China's New Draft Administrative Measures For Management Of Medical Representatives

China Healthcare

AP

Arnold & Porter

Quiet On The Set? Forbidding FDA To Take Photographs During An Inspection Can Be Regrettable

China Healthcare

HP

Hyman, Phelps, & McNamara

Cannabis Law And Legislation In China

The PRC Drugs Prohibition Law classifies "marijuana"—products from the plant Cannabis sativa that contain substantial amounts of tetrahydrocannabinol (THC)—as drugs and prohibits its use in any form

CC

CMS, China

Supreme People's Court Issued Interpretation On Punitive Damages For Food And Drug Disputes

The Supreme People's Court ("SPC") of the People's Republic of China ("PRC") has recently promulgated the Interpretation on Several Issues Concerning the Application of Law to the Trial of Cases of Disputes over Punitive Damages in Food and Drugs ("Interpretation"), taking effect from August 22, 2024.

China Healthcare

CC

CMS, China

China's New Draft Administrative Measures For Management Of Medical Representatives

On November 28, 2024, China's National Medical Products Administration (NMPA, 国家药品监督管理局), China's equivalent of the U.S. Food and Drug Administration...

China Healthcare

AP

Arnold & Porter

Quiet On The Set? Forbidding FDA To Take Photographs During An Inspection Can Be Regrettable

A recent Warning Letter reflects an FDA citation of a company for refusing to permit FDA Investigators to take photographs during an inspection.

China Healthcare

HP

Hyman, Phelps, & McNamara

Relaxation Of Long-Standing Restrictions On Foreign Investment In The Healthcare Sector In China

China Healthcare

MW

McDermott Will & Emery

BIOSECURE Act: Anticipated Movement, Key Provisions, And Likely Impact

Last night, the House of Representatives passed the BIOSECURE Act (BIOSECURE or the Act) by a bipartisan vote of 306 to 81.

China Healthcare

FL

Foley & Lardner

China Expands Pilot Program For Foreign Investment In The Healthcare Sector

On September 7, China's Ministry of Commerce, the National Health Commission, and the National Medical Products Administration issued a notice announcing the expansion of pilot programs for foreign investment...

China Government

SM

Sheppard Mullin Richter & Hampton

对药品专利权期限补偿的解析和思考

在过去数年中，我国医药行业发展迅速，已成为全球最大、最活跃的医药市场之一。为了进一步鼓励药品研发创新...

CP

CCPIT Patent & Trademark Law Office

China Proposed New Anti-Monopoly Guidelines For The Pharmaceutical Sector

On August 9, 2024, China's State Administration for Market Regulation (SAMR) released a draft of the Anti-Monopoly Guidelines for the Pharmaceutical Sector (hereinafter referred to as the "AMGP")...

China Healthcare

SM

Sheppard Mullin Richter & Hampton

중국 국가지식산권국장, 외국인 투자기업과 지식재산권 보호에 관해 논의

K

Kangxin

CNIPA And Italy's Ministry Of Agriculture, Food Sovereignty And Forestry Sign MoU On Geographical Indications

China Healthcare

AC

AFD China

The Demand And Challenges Of Patent Protection For Combination Drug Therapy

China Healthcare

Lung Tin IP Attorneys

Revisions Of The Implementing Regulations Of The Patent Law And The Patent Examination Guidelines: Comments On Several Key Issues

Lung Tin IP Attorneys

"保险+互联网医疗"业态的合规要点

China Insurance

AB

AnJie Broad Law Firm

"互联网+医疗"领域的主要业务类型及其关注热点（续）Q&A

China Healthcare

AB

AnJie Broad Law Firm

China And France Renew Protocol For Cooperation On Agricultural And Food Geographical Indications

AC

AFD China

医药许可与BD合作交易近期常见争议及对交易文件起草的启示

China Healthcare

AB

AnJie Broad Law Firm

药品许可交易概览及核心法律条款

China Healthcare

AB

AnJie Broad Law Firm

Commission Makes First Use Of IPI, Targeting Medical Device Procurement Markets In China

Worldwide Healthcare

VB

Van Bael & Bellis

中医薬基盤モデル「デジタル・スマート本草」が天津で発表

China Healthcare

K

Kangxin

对《最高人民法院知识产权法庭裁判要旨摘要（2023）》所涉药品专利链接诉讼案件的解读（二）

AB

AnJie Broad Law Firm

Third Revision Of The "Implementing Regulations Of The Patent Law Of The People's Republic Of China" – Compensation For Patent Term

AC

AFD China

对《最高人民法院知识产权法庭裁判要旨摘要（2023）》所涉药品专利链接诉讼案件的解读（一）

China Healthcare

AB

AnJie Broad Law Firm

最高人民法院知的財産権法廷裁判要旨（2023）

K

Kangxin

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More